From GlobeNewswire: 2024-12-31 15:26:02

Bionano Genomics, Inc. (Nasdaq: BNGO) has entered into a settlement agreement and amendment to defer the December 2024 amortization payment and reduce payments from January 2025 to July 2025. The Amendment also lowers the conversion price of outstanding senior secured convertible debentures from $2.00 to $0.27 and issues 5,000,000 shares of common stock. The company’s capital structure is strengthened, improving liquidity for driving genome mapping adoption and maximizing shareholder value. The offering was advised by Canaccord Genuity and was not a public offering. Additional details will be in a Form 8-K filing with the Securities and Exchange Commission.

Bionano is a provider of genome analysis solutions that enable researchers and clinicians to address biological and medical questions. The company’s mission is to transform genome perception through OGM solutions, diagnostic services, and software. OGM solutions cover basic, translational, and clinical research, along with a platform-agnostic genome analysis software. A non-public offering of common stock was made with certain terms. Bionano’s OGM products are for research use only. Forward-looking statements regarding the company’s capital structure, liquidity, and market expansion are included in the press release.



Read more at GlobeNewswire: Bionano Announces Amendment to Senior Secured Convertible